Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) was the recipient of a significant growth in short interest in September. As of September 30th, there was short interest totalling 2,398,479 shares, a growth of 284.3% from the September 15th total of 624,046 shares. Currently, 6.8% of the company’s stock are sold short. Based on an average daily volume of 1,318,709 shares, the days-to-cover ratio is presently 1.8 days.

In other news, insider Barbara White bought 38,000 shares of the stock in a transaction on Wednesday, August 17th. The shares were purchased at an average price of $3.15 per share, for a total transaction of $119,700.00. Following the completion of the purchase, the insider now directly owns 161,067 shares of the company’s stock, valued at approximately $507,361.05. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CFO Sean F. Moran bought 30,800 shares of the stock in a transaction on Thursday, September 8th. The stock was purchased at an average price of $5.12 per share, for a total transaction of $157,696.00. Following the purchase, the chief financial officer now directly owns 330,110 shares of the company’s stock, valued at $1,690,163.20. The disclosure for this purchase can be found here. 11.60% of the stock is owned by company insiders.

CRBP has been the topic of a number of recent research reports. Aegis set a $12.00 target price on Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research note on Monday, September 19th. Cantor Fitzgerald initiated coverage on Corbus Pharmaceuticals Holdings in a research note on Tuesday, October 4th. They issued a “buy” rating and a $17.00 target price on the stock.

Shares of Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) opened at 9.34 on Friday. Corbus Pharmaceuticals Holdings has a 12 month low of $1.01 and a 12 month high of $10.78. The firm’s market cap is $408.61 million. The firm has a 50 day moving average price of $6.53 and a 200-day moving average price of $3.68.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last posted its quarterly earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.08) by $0.03. Corbus Pharmaceuticals Holdings had a negative net margin of 890.44% and a negative return on equity of 107.10%. On average, analysts predict that Corbus Pharmaceuticals Holdings will post ($0.40) EPS for the current fiscal year.

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases.

5 Day Chart for NASDAQ:CRBP

Receive News & Stock Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related stocks with our FREE daily email newsletter.